Log in met Medi-Access

Wilt u het gehele artikel lezen?
Log in met Medi-Access om verder te lezen

FDA Approves Risankizumab (Skyrizi) for Psoriatic Arthritis

Medscape: Rheumatology | Geplaatst op 22.01.2022 02:32

The approval is the second indication for the anti-interleukin 23 monoclonal antibody after approval for plaque psoriasis was granted in 2019. Medscape Medical News